Optimal designs for clinical trials with second-order polynomial treatment effects

Statistical Methods in Medical Research

Volumn 16, Issue 6, 2007, Pages 523-537

  Winkens, Bjorn ^a   Schouten, Hubert J A ^a   Van Breukelen, Gerard J P ^a   Berger, Martijn P F ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE;

ANALYSIS OF VARIANCE; ARTICLE; BODY COMPOSITION; BODY FAT; BUDGET; CALORIC INTAKE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COST OF ILLNESS; COVARIANCE; DRUG RESPONSE; ENERGY EXPENDITURE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEASUREMENT ERROR; METHODOLOGY; OUTCOME ASSESSMENT; PROCESS OPTIMIZATION; RANDOMIZED CONTROLLED TRIAL; RESOURCE MANAGEMENT; SAMPLE SIZE;

CLINICAL TRIALS AS TOPIC; MODELS, STATISTICAL; NETHERLANDS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 36949028320     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280206071847     Document Type: Article

References (16)

1. Overall JE, Doyle SR. Estimating sample sizes for repeated measurement designs. Controlled Clinical Trials 1994; 15: 100-23.
2. Raudenbush SW, Liu X-F. Effects of study duration, frequency of observation, and sample size on power in studies of group differences in polynomial change. Psychological Methods 2001; 6: 387-401.
3. Bloch DA. Sample size requirements and the cost of a randomized clinical trial with repeated measurements. Statistics in Medicine 1986; 5: 663-67.
4. Lui K-J, Cumberland WG. Sample size requirement for repeated measurements in continuous data. Statistics in Medicine 1992; 11: 633-41.
5. Atkinson AC, Donev AN. Optimum experimental designs. Clarendon Press, 2002.
6. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. British Medical Journal 1990; 300: 230-35.
7. Pham B, Cranney A, Boers M, Verhoeven AC, Wells G, Tugwell P. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. Journal of Rheumatology 1999; 26: 712-16.
8. Schiff M. A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies. Clinical Therapeutics 2003; 25: 993-1001.
9. Wong WK. A unified approach to the construction of minimax designs. Biometrika 1992; 79: 611-19.
10. Agteresch HJ, Rietveld T, Kerkhofs LGM, Van den Berg JWO, Wilson JHP, Dagnelie PC. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. Journal of Clinical Oncology 2002; 20: 371-78.
11. Diggle PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data. Oxford University Press, 1996.
12. Moerbeek M, van Breukelen GJP, Berger MPF. Design issues for experiments in multilevel populations. Journal of Educational and Behavioral Statistics 2000; 25: 271-84.
13. Ouwens JNM, Tan FES, Berger MPF. Maximin D-optimal designs for longitudinal mixed effects models. Biometrika 2002; 58: 735-41.
14. Berger MPF, Tan FES. Robust designs for linear mixed effects models. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2004; 53: 569-81.
15. Bischoff W. Determinant formulas with applications to designing when the observations are correlated. Annals of the Institute of Statistical Mathematics 1995; 47: 385-99.
16. Huang M-NL, Chang F-C, Wong WK. D-optimal designs for polynomial regression without an intercept. Statistica Sinica 1995; 5: 441-58.